April 24, 2024 11:08 AM EDTUpdated 11:57 AM

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Jared Whitlock

Features Editor

Lia DeGroot

Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Jared Whitlock

Features Editor

Lia DeGroot

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Features Editor

Sign up to read this article for free.

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues